Trial Profile

The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2025 According to a Milestone Pharmaceuticals media release, trial to be presented at American College of Cardiology Annual Meeting on March 30, 2025.
18 Nov 2024 Results assessing the frequency and patterns of paroxysmal supraventricular tachycardia episodes among patients opting for acute drug treatment presented at the American Heart Association Scientific Sessions 2024.
02 Sep 2024 Results assessing Quality of life measures with etripamil self-administration for acute episodes of paroxysmal supraventricular tachycardia in a medically unsupervised setting presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com